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1CROSS-SECTIONAL ANALYSIS OF THE MEDIUM-TERM IMPACT OF 
BARIATRIC SURGERY ON PHARMACOLOGICAL EXPENDITURE
Abstract
Introduction: Obesity and associated diseases represent an important health and 
economic problem since pharmacological treatment for many of these pathologies needs 
lifelong subsidies. Theoretically, bariatric and metabolic surgery decreases the 
medication requirements of patients for these diseases but may result in other types of 
pharmacological needs. This study aims to demonstrate whether there is a real decrease 
in pharmacological expenditure after bariatric surgery.
Material and methods: Retrospective cross-sectional analysis of patients who 
were treated in our centre between 2012 and 2015, comparing different associated 
comorbidities and pharmacological expenses one month before and 2 years after 
surgery.
Results: A total of 280 patients underwent surgery; 36.8% of patients had 
diabetes, 50% hypertension, 11.1% cardiovascular disease, 13.9% osteoarticular 
disease, 13.6% endocrine disorders, 30% non-diabetic metabolic disorders, and 35.4% 
psychiatric disease. At 2 years after surgery, 12.1% of patients continued medication for 
diabetes, and 28.2% for arterial hypertension. Additionally, 9.3% of patients still had 
cardiovascular disease, 7.1% osteoarticular disease, 10.4% endocrine disorder, 13.9% 
non-diabetic metabolic disorder, and 29.3% psychiatric disease. Median 
pharmacological expenditure before surgery was 17 euros per month; 2 years after 
surgery, it was 12 euros a month, resulting in a significant decrease (p<0.001).
2Conclusions: In a 2-year follow-up after bariatric surgery, a decreased 
prevalence of obesity-related diseases and associated pharmacological expenditure was 
observed, showing the efficiency of this intervention over the medium term and 
potentially over the long term.
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3Introduction
Overweight and obesity as well as associated pathologies are a serious health 
problem for both developed and underdeveloped countries; currently, these conditions 
are considered a global pandemic1,2.
Bariatric surgery results in long-term improvement and decreased body weight; 
moreover, in many cases, obesity-related diseases are resolved3.
These obesity-related diseases (directly or indirectly associated) are usually 
controlled by means of pharmacotherapy. This pharmacological need is usually lifelong 
if obesity is not resolved or improved, representing important costs for different health 
systems or patients themselves4.
Two years after surgery is the time when the majority of patients get the 
maximum benefit from it, although in a significant number of patients there will be a 
recovery of weight in the following 2 -3 years (50% will recover 25% of the maximum 
weight lost) which would lead to the recurrence of comorbidities and, potentially, of the 
cost of the medication.
This study aims to analyse the pharmacological needs in patients undergoing 
surgery for morbid obesity, comparing the time prior to surgery and after a two-year 
follow-up to assess whether there is a real decrease in these needs and associated 
pharmacological expenditure.
4Material and methods
The present cross-sectional retrospective study was carried out between 2012 
and 2015; 280 patients undergoing bariatric surgery were evaluated. Clinical support 
programmes were used for the collection of data, where all the pathologies and 
medication corresponding to each patient are included.
The following patient demographic and clinical variables were collected one 
month prior to surgery: age, gender, weight, height and BMI, as well as comorbidity 
factors associated with morbid obesity, considering that these comorbidities involve 
pharmacotherapy in every case. These comorbidities included arterial hypertension 
(HBP); diabetes (DM); obstructive sleep apnoea syndrome (OSAS) and the use of 
continuous positive airway pressure (CPAP); cardiovascular, osteoarticular, endocrine, 
metabolic, and psychiatric pathologies; and other comorbidities that were initially 
related to morbid obesity (hyperuricaemia, anaemia, hypocalcaemia, and hiatal hernia). 
The total pharmacological expenditure for each patient is expressed as the median at the 
time of analysis and not as an absolute value. In this price, CPAP is not included, since 
only pharmacological costs are considered. This total expense was calculated in euros 
for each patient during a period of 30 days immediately before and 2 years after surgery. 
This first study is performed at 2 years, knowing that it is the time of greatest benefits of 
bariatric surgery, waiting for a new comparison at 5 years.
In turn, the following surgical factors were considered: ASA anaesthetic, type of 
bariatric surgery (sleeve or bypass), postoperative complications (haemorrhage, fistula, 
pneumonia, or other), need for reintervention in the same admission, hospital stay (in 
days), aftermath, understanding the pathology that occurs throughout the follow-up as a 
direct consequence of bariatric surgery. This pathology included cholelithiasis, 
5incisional hernia, anastomotic complications (stenosis or perforations), and internal 
hernias, as well as the need for reintervention (revision surgery).
Vertical gastrectomy (VG) or a gastric sleeve was initially indicated in patients 
with BMI>50 kg/m2 as the first intervention to facilitate a second intervention with a 
mixed technique. Subsequently, given the good results obtained, VG was extended to 
BMI between 35 and 40 with greater comorbidities. These comorbidities included 
age>60 years; high-risk with severe hepatic, cardiac pathology, or chronic kidney 
disease; and gastric premalignant pathology.
Gastric bypass (RYGBP) was indicated for patients with BMI<50 and metabolic 
disorders, especially type II DM. In the latter patients (DM), a different RYGBP 
approach was carried out to try to improve the metabolic component as defined later in 
the text. Similarly, the eating habits of patients were considered, and RYGBP was 
chosen for patients who peck at food. This surgery is the first choice for these patients 
due to the high failure rate of restrictive techniques. All patients included in the study 
underwent laparoscopic surgery.
The results on the variables allowed us to compare the total cost of all 
comorbidities two years after surgery with the previous cost. The included variables 
were weight and BMI, persistence or onset of comorbidities, including those in addition 
to comorbidities mentioned before surgery, those related to vitamin and nutritional 
deficits secondary to the surgery, and total median pharmacological expenditure.
Patients undergoing bariatric surgery—VG, conventional RYGBP 
(biliopancreatic pouch 60 cm and food pouch 150-200 cm), and metabolic RYGBP 
(biliopancreatic pouch 100 cm and food pouch 150-200 cm)—were included, with ages 
6between 18 and 60 years according to the established indications. Gastric band removal 
and other revision surgeries were excluded from the study.
Continuous variables are presented as the median (interquartile range), and 
qualitative variables are presented as frequencies (percentages). Categorical variables 
were compared using Fisher's exact test or McNemar’s test. Continuous variables were 
compared using the Mann-Whitney U test or Wilcoxon test. For statistical analysis, the 
SPSS® software package, version 20 (IBM, Armonk, New York, United States) was 
used. The risk ratio with its safety confidence intervals at 95% (95%CI) for paired data 
was calculated before/after each intervention to compare the risk reduction intensity of 
type II DM after surgery involving the three surgical techniques. In all cases, statistical 
significance was considered at p<0.05.
7Results
Table 1 shows demographic results and comorbidity factors one month prior to 
surgery. Note that female was the predominant gender for this intervention. BMI was 
higher in patients undergoing VG, which makes sense considering the first indications 
for this technique. In patients with metabolic pathology (hypertension, DM2 and 
dyslipidaemia), RYGBP predominates over restrictive techniques.
Table 2 shows the surgical factors. Most patients were ASA III. Surgical 
complications were rare for both techniques. However, bleeding from stitches was the 
most frequent complication, which was more frequent in RYGBP. Only one 
reintervention was necessary during the 3 years of the study. Postoperative stay (in 
days) was similar for both techniques but somewhat longer for RYGBP.
Table 3 shows the results at two years after surgery in which postoperative 
weight loss and pathologies were collected. The significant OSAS decrease and 
associated CPAP use was striking.
Table 4 shows a comparison between the data one month before and 2 years 
after surgery. Weight loss was significant, as well as decreased comorbidities and 
associated medication for HBP, DM2, metabolic and osteoarticular pathology. 
However, for cardiovascular, endocrine and psychiatric pathology, the decrease after 
surgery was nonsignificant. Note that two years after the intervention, there was a 
significant expenditure increase related to other treatments involving nutritional and 
vitamin deficits, which require pharmacological support in most patients after bariatric 
surgery, especially in malabsorptive techniques.
Regarding VG, the before/after risk ratio for diabetes II was 0.36 (95%CI: 0.22 
to 0.39; p<0.001). A similar ratio, 0.34, was obtained for metabolic bypass (95%CI: 
80.25-0.47, p<0.001). For conventional bypass, the risk reduction intensity for diabetes II 
was somewhat lower, with a risk ratio of 0.29 (95%CI: 0.07-1.14), but this difference 
was nonsignificant (p=0.125) due to the low diabetes prevalence (5%) before surgery 
for this group of patients.
Table 5 shows the results related to pharmacological expenditure. The median 
decrease in the total expense at 2 years after surgery was significant; a significantly 
larger proportion of cases had decreased expenditure compared to the proportion of 
cases showing increased expenditure or no variation. Figure 1 shows this general 
tendency towards decreased spending, although the existence of a certain level of 
variability can be observed, represented by a considerable number of cases with atypical 
or extreme values.
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Morbid obesity is a serious health problem and poses a challenge for the public 
health system budget. Thus, health interventions that manage to reduce obesity and its 
associated diseases will unequivocally result in significant savings in health costs for 
the population5.
The simplest way to classify the economic burden of obesity is to divide 
expenses into direct and indirect costs6,7. Direct costs are the easiest to determine and 
include those associated with the diagnosis and treatment of the disease, cost of 
medication and cost of hospital and home services. By contrast, indirect costs are 
related to morbidity and mortality and reflect the loss of salary due to illness or 
disability and a loss of future earnings due to premature death. The present study 
considered only direct costs related to the pharmacological expenditure derived from 
obesity-associated comorbidities.
In a review by Von Legerke et al (2011)8, data were provided on 19 European 
studies assessing the impact of obesity on the cost of various diseases. In type I DM, 
obesity increases health costs by € 812 per year and by € 454 in type II DM, which 
implies a 78% higher per-capita cost when obesity and diabetes are associated.
The Delphi9 prospective study showed that in Spain, obesity is responsible for 
43% of the total cost of type II DM, 32% in arthropathies and more than 30% of the cost 
of heart diseases. These results approximate those collected in our study; considering 
that the number of patients and follow-up years were lower, we observed that 36.8% of 
obese patients were diabetic, 13.9% had osteoarticular disorders, and 11.1% had 
cardiovascular disorders.
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Several studies and meta-analyses comprise 3,000 to 12,000 patients and include 
the evolution of comorbidities after bariatric surgery10,11,12. Generally, these studies 
have shown remission of type II DM in 86.6% of patients13 and improvement or 
resolution of hyperlipidaemia in 70%, hypertension in 61.7%, OSAS in 83%, and 
coronary heart disease in 32-56%.
In our study, after two years of surgery, the resolution of comorbidities was 
recorded without considering improvement since by definition in the prevalence design 
of the study, the existence of pathology is related to an active pharmacological 
treatment. Thus, if medication use persists, even at a lower dose, this comorbidity 
remains prevalent. In this sense, the decreased number of patients taking anti-diabetic 
drugs, indicating the resolution of type II DM, was 24.7%. If we break down the result 
between VG and RYGBP, unsurprisingly, the malabsorptive technique obtained better 
results in absolute values, although the selection of cases to indicate either technique 
must be considered. However, when calculating risk ratios, the intensity of the 
differences for GV and metabolic RYGBP were quite similar in both cases. Regarding 
the percentage of patients taking antihypertensive drugs, the decrease was 21.8%; for 
osteoarticular pathology, the decrease was 6.8% and that for hyperlipidaemia was 
16.1%.
The lowest decrease, which was nonsignificant, was found in cardiovascular, 
endocrine and psychiatric pathologies. This small decrease may be due to the less direct 
relationship with obesity as with the aforementioned pathologies. Regarding 
cardiovascular disease, the analysis shows that anticoagulant and antiplatelet drugs were 
most frequently used when treating arrhythmias and as prophylaxis after placing cardiac 
devices. The use of these drugs remained constant after bariatric surgery as there is no 
relationship with the resolution of established ischaemic diseases.
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Regarding endocrine pathology, the most commonly used drug was 
levothyroxine in relation to hypothyroidism. In these cases, regardless of the cause that 
triggers the issue, most patients continue to use levothyroxine after surgery but at a 
different dose. Psychiatric pathology should disappear after weight loss induced by 
bariatric surgery to improve physical appearance and quality of life. However, in many 
patients, this pathology remains and can even result in an increased need for drugs. In 
these cases, we must consider that these patients are chronic consumers who often have 
personality disorders or basic pathologies that make complete resolution of symptoms 
very complicated.
Regarding medication savings, the literature shows controversial results due to 
the variety of different studies on how to measure comorbidities and their resolution and 
the surgical techniques used. In this sense, reaching a general conclusion is complicated. 
In a prospective study by Sampalis14 (2014), there was an average decrease in 
treatments per patient by 66%, which was the cut-off point for the cost-effectiveness 
ratio at 2.5 years after surgery. Máklin 201115 concluded that bariatric surgery 
represents savings of € 16,130 per treated patient. Christou16 showed that operated 
patients had significantly fewer cancer diagnoses (2 vs. 8%), fewer heart problems (5 
vs. 27%), fewer infections (9 vs. 37%), less arthritis (5 vs. 12%), and fewer respiratory 
problems (3vs. 11%). The health cost of the non-operated group far exceeded that of the 
operation after the third year of follow-up. In our study, the total expenditure decrease 
after two years of bariatric surgery was significant, with the median decreasing from 17 
euros per month to 12 and differences depending on the type of pathology as mentioned 
above.
In general terms, it can be said that, although in 55% of cases there is a decrease 
in total pharmacological expenditure, in 45% it remains unchanged or even experiences 
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an increase (14% unchanged and 31% with increase). It is necessary to emphasize the 
role played by prescriptions related to vitamins and nutritional supplements, since their 
increase after bariatric surgery is 47.9%, being the highest value of differences at two 
years (p<0.001).
The comparison between obesity costs and bariatric surgery is also complex, 
especially considering different countries, since financing in the different European 
health systems differ radically from that in the USA. The Spanish National Health 
System has defined a DRG that encompasses the surgical treatment for obesity with an 
average cost of € 7,468. Studies show an investment recovery and spending reduction 
after 4 to 5 years, which means a profitable investment over the medium term17,18,19-20. 
The present study did not include bariatric surgery costs, only the direct cost implied by 
the improvement in comorbidity and subsequent improvement in pharmacological 
expenditure, without comparing it to intervention costs.
Given our results, the strengths of this study are the high number of patients, 
which allows greater accuracy, as well as the large number of evaluated variables that 
offers a wide range of analysis possibilities. However, we measured pharmacological 
expenditure in euros per month; even though this measure was carried out with 
maximum objectivity, it might represent a weakness because of its lower reproducibility 
due to the large fluctuation in drug prices and dose variability.
Thus, we conclude that this study demonstrates a decrease in pharmacological 
expenditure two years after bariatric surgery, implying the crucial role of this 
intervention in the resolution of comorbidities associated with morbid obesity. It should 
be considered that these interventions involve metabolic changes, leading multiple 
patients to consume vitamin or nutritional supplements, sometimes for life. However, 
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given the results and considering the great benefits, this expense is acceptable and 
cannot be compared to the costs associated with previous comorbidities.
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Table 1. Preoperative demographic and comorbidity factors.
Table 2. Surgical factors and general outcomes of surgery.
Table 3. Results at 2 years.
Table 4. Differences, preoperative phase - 2 years.
Table 5. Analysis of pharmacological expenditures
Figure 1. Difference in pharmacological expenditures. Preoperative treatment 
expenditure and treatment expenditure at 2 years. Circles: outliers; Squares: extreme 
values

TOTAL SLEEVE BYPASS
P-
Value 
n=280 n=107 n=173  
      
Age* 52 (43-57) 51 (41-57) 52 (44-58) 0.082†
      
Gender
           Male 90 (32.1%) 35 (32.7%) 55 (31.8%) 0.90††
Female 190 (67.9%) 72 (67.3%) 118 (68.2%)
      
Weight kg*
125 (113-
142)
141 (124-
148)
120 (110-
132) <0.001†
      
BMI * 47 (43-52) 53 (48-58) 44 (42-47) <0.001†
      
Arterial hypertension 140 (50%) 52 (48.6%) 88 (50.9%) 0.80††
      
Diabetes
103 
(36.8%) 28 (26.2%) 75 (43.4%) 0.005††
      
OSAS
240 
(85.7%) 90 (84.1%)
150 
(86.7%) 0.60††
      
CPAP use
237 
(84.6%) 90 (84.1%) 147 (85%) 0.87††
      
Cardiovascular 
comorbidity 31 (11.1%) 16 (15%) 15 (8.7%) 0.12††
      
Osteoarticular 
comorbidity 39 (13.9%) 16 (15%) 23 (13.3%) 0.72††
      
Endocrine comorbidity 38 (13.6%) 8 (7.5%) 30 (17.3%) 0.02††
      
Metabolic comorbidity 84 (30.0%) 27 (25.2%) 57 (32.9%) 0.18††
      
Psychiatric comorbidity 99 (35.4%) 36 (33.6%) 63 (36.4%) 0.70††
      
Other comorbidity 18 (6.4%) 4 (3.7%) 14 (8.1%) 0.21††
      
     
* Median (interquartile range); † (Mann-Whitney); †† (Fisher’s exact)
TOTAL SLEEVE BYPASS
P-
Value 
n=280 n=107 n=173  
      
Previous surgery
129 
(46.1%) 43 (40.2%)
86 
(49.7%) 0.14††
      
ASA
I 1 (0.4%) 0 1 (0.6%) 0.89††
II 24 (8.6%) 10 (9%) 14 (8.1%)
III 255 (91%) 97 (91%)
158            
(91.3%)
      
Postoperative 
complications
Haemorrhage 5 (1.8%) 1 (0.9%) 4 (2.3%) 0.25††
Fistula 1 (0.4%) 0 1 (0.6%)
Pneumonia 1 (0.4%) 1 (0.9%) 0
Other 4 (1.4%) 0 4 (2.3%)
      
Reintervention 1 (0.4%) 0 1 (0.6%) 1††
      
Postoperative stay * 5 (4-5) 5 (3-5) 5 (4-6) 0.008†
      
Aftermath
47 
(16.8%) 22 (20.6%)
25 
(14.5%) 0.19††
      
Reintervention by 
sequelae 40 (89%) 18 (86%) 22 (92%) 0.65††
      
* Median (interquartile range); † (Mann-Whitney); †† (Fisher’s exact)
TOTAL SLEEVE BYPASS P-Value 
n=280 n=107 n=173
     
Weight kg*
90 (78-
103) 100 (85-113) 85 (76-96) <0.001†
     
BMI * 33 (30-38) 37 (33-43) 32 (28-35) <0.001†
     
High blood pressure treatment 79 (28.2%) 33 (30.8%) 46 (26.6%) 0.49††
     
Anti-diabetic treatment 34 (12.1%) 10 (9.3%) 24 (13.9%) 0.35††
     
OSAS 18 (6.4%) 13 (12.1%) 5 (2.9%) 0.004††
     
CPAP use 17 (6.1%) 13 (12.1%) 4 (2.3%) 0.001††
     
Cardiovascular treatment 26 (9.3%) 14 (13.1%) 12 (6.9%) 0.09††
     
Osteoarticular treatment 20 (7.1%) 10 (9.3%) 10 (5.8%) 0.34††
     
Endocrine treatment 29 (10.4%) 6 (5.6%) 23 (13.3%) 0.03††
     
Metabolic treatment 39 (13.9%) 19 (17.8%) 20 (11.6%) 0.16††
     
Psychiatric treatment 82 (29.3%) 27 (25.2%) 55 (31.8%) 0.28††
     
Other treatments
157 
(56.1%) 54 (50.5%)
103 
(59.5%) 0.14††
     
Preoperative treatment cost * 17 (2-57) 14 (0-41) 24 (3-68) 0.14†
     
Treatment cost at 2 years * 12 (0-28) 11 (0-25) 13 (0-28) 0.44†
     
* Median (interquartile range); † (Mann-Whitney); †† (Fisher’s exact)
YEAR 
2
YEAR 
0 Difference P-Value 
     
Weight kg* 90 125 -35 <0.001†
     
BMI * 33 47 -14 <0.001†
     
High blood pressure treatment 28.2% 50% -21.8% <0.001††
     
Anti-diabetic treatment 12.1% 36.8% -24.7% <0.001††
     
OSAS 6.4% 85.7% -79.3% <0.001††
     
CPAP use 6.1% 84.6% -78.5% <0.001††
     
Cardiovascular treatment 9.3% 11.1% -1.8% 0.30††
     
Osteoarticular treatment 7.1% 13.9% -6.8% <0.001††
     
Endocrine treatment 10.4% 13.6% -3.2% 0.004††
     
Metabolic treatment 13.9% 30% -16.1% <0.001††
     
Psychiatric treatment 29.3% 35.4% -6.1% 0.04††
     
Other treatments at 2 years 56.1% 6.4% +49.7% <0.001††
     
* Median; † (Wilcoxon); †† (McNemar)
Year 0 (n=280) 2 years (n=280)
Lowest expenditure 0 0
Highest expenditure 241 220
Median expenditure (95%CI) 17 (11-27) * 12 (9-15) *
Interquartile range 2 - 58 0-27
Cases with increased expenditure (%) 88 (31%) **
Cases with decreased expenditure (%) 153 (55%) **
Cases without expenditure change (%) 39 (14%) **
* p <0.001 (Wilcoxon); ** p < 0.001 (Fisher’s exact); CI: confidence interval
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